Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

Both glial cell line‐derived neurotrophic factor (GDNF) and its recently discovered congener, neurturin (NTN), have been shown to excert neuroprotective effects on lesioned nigral dopamine (DA) neurons when administered at the level of the substantia nigra. In the present study, we have explored the relative in vivo potency of these two neurotrophic factors using two alternative routes of administration, into the striatum or the lateral ventricle, which may be more relevant in a clinical setting. In rats subjected to an intrastriatal (IS) 6‐hydroxydopamine (6‐OHDA) lesion, GDNF and NTN were injected every third day for 3 weeks starting on the day after the 6‐OHDA injection. GDNF provided almost complete (90–92%) protection of the lesioned nigral DA neurons after both IS and intracerebroventricular (ICV) administration. NTN, by contrast, was only partially effective after IS injection (72% sparing) and totally ineffective after ICV injection. Although the trophic factor injections protected the nigral neurons from lesion‐induced cell death, the level of expression of the phenotypic marker, tyrosine hydroxylase (TH), was markedly reduced in the rescued cell bodies. The extent of 6‐OHDA‐induced DA denervation in the striatum was unaffected by both types of treatment; consistent with this observation, the high rate of amphetamine‐induced turning seen in the lesioned control animals was unaltered by either GDNF or NTN treatment. In the GDNF‐treated animals, and to a lesser extent also after IS NTN treatment, prominent axonal sprouting was observed within the globus pallidus, at the level where the lesioned nigrostriatal axons are known to end at the time of onset of the neurotrophic factor treatment. The results show that GDNF is highly effective as a neuroprotective and axon growth‐stimulating agent in the IS 6‐OHDA lesion model after both IS and ICV administration. The lower efficacy of NTN after IS, and particularly ICV, administration may be explained by the poor solubility and diffusion properties at neutral pH.

[1]  Anders Björklund,et al.  Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.

[2]  J. Milbrandt,et al.  Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons , 1998, The Journal of Neuroscience.

[3]  S. Reppert,et al.  A Clockwork Explosion! , 1998, Neuron.

[4]  I. Fariñas,et al.  GFRα1 Is an Essential Receptor Component for GDNF in the Developing Nervous System and Kidney , 1998, Neuron.

[5]  H. Gao,et al.  [Neurturin: a relative of glial-cell-line-derived neurotrophic factor]. , 1998, Sheng li ke xue jin zhan [Progress in physiology].

[6]  Blunt,et al.  Long‐term protection of the rat nigrostriatal dopaminergic system by glial cell line‐derived neurotrophic factor against 6‐hydroxydopamine in vivo , 1998, The European journal of neuroscience.

[7]  A. Björklund,et al.  Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease , 1997, Neurobiology of Disease.

[8]  T. Hagg,et al.  Glial cell line‐derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats , 1997, The Journal of comparative neurology.

[9]  L. Olson,et al.  Neurturin and Glial Cell Line-Derived Neurotrophic Factor Receptor-β (GDNFR-β), Novel Proteins Related to GDNF and GDNFR-α with Specific Cellular Patterns of Expression Suggesting Roles in the Developing and Adult Nervous System and in Peripheral Organs , 1997, The Journal of Neuroscience.

[10]  A. Björklund,et al.  Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease , 1997, Neuroscience.

[11]  Jimi Adu,et al.  Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase , 1997, Nature.

[12]  Barbara Moffat,et al.  A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor , 1997, Nature.

[13]  J. Milbrandt,et al.  TrnR2, a Novel Receptor That Mediates Neurturin and GDNF Signaling through Ret , 1997, Neuron.

[14]  S. Jiao,et al.  Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery , 1997, Neuroscience.

[15]  S. Jiao,et al.  Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection , 1997, Brain Research.

[16]  J. Milbrandt,et al.  Neurturin, a relative of glial-cell-line-derived neurotrophic factor , 1996, Nature.

[17]  A. Björklund,et al.  Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s Disease , 1996, The Journal of Neuroscience.

[18]  A. Buj-Bello,et al.  Characterization of a multicomponent receptor for GDNF , 1996, Nature.

[19]  J. Louis,et al.  GDNF–Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-α, a Novel Receptor for GDNF , 1996, Cell.

[20]  E. Arenas,et al.  Functional receptor for GDNF encoded by the c-ret proto-oncogene , 1996, Nature.

[21]  A. Björklund,et al.  Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat , 1996, Neuroscience.

[22]  D. Russell,et al.  Glial Cell Line‐derived Neurotrophic Factor: the Lateral Cerebral Ventricle as a Site of Administration for Stimulation of the Substantia Nigra Dopamine System in Rats , 1996, The European journal of neuroscience.

[23]  D. Altieri,et al.  In vivo immunosuppression by targeting a novel protease receptor , 1996, Nature.

[24]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[25]  C. Shults,et al.  Intrastriatal injection of GDNF attenuates the effects of 6‐hydroxydopamine , 1996, Neuroreport.

[26]  D J Brooks,et al.  GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET , 1995, Neuroreport.

[27]  A. Björklund,et al.  Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Goldman,et al.  Hu protein as an early marker of neuronal phenotypic differentiation by subependymal zone cells of the adult songbird forebrain. , 1995, Journal of neurobiology.

[29]  L. Olson,et al.  Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Granholm,et al.  Glial cell line‐derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons , 1995, The Journal of comparative neurology.

[31]  D. Gash,et al.  GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo , 1995, Brain Research.

[32]  R. Vandlen,et al.  Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.

[33]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[34]  John L. Hudson,et al.  Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo , 1994, Neuroscience Letters.

[35]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[36]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[37]  S. Hunt,et al.  c-jun Expression in substantia nigra neurons following striatal 6-hydroxydopamine lesions in the rat , 1993, Neuroscience.

[38]  DJ Wigston,et al.  The dependence of motoneurons on their target muscle during postnatal development of the mouse , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[39]  A. Björklund,et al.  Intrinsic Organization and Connectivity of Intrastriatal Striatal Transplants in Rats as Revealed by DARPP‐32 Immunohistochemistry: Specificity of Connections with the Lesioned Host Brain , 1989, The European journal of neuroscience.

[40]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[41]  Jonathan K. Crane,et al.  Non-dopaminergic nigrostriatal pathway , 1981, Brain Research.

[42]  U. Ungerstedt,et al.  Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.